Structure-based drug design is also known as what?

Structure-based drug design is also known as what?

• A. Rational drug design
• B. Empirical drug design
• C. Random discovery
• D. Targeted screening

Answer: (A)

Using the target’s 3D structure to guide chemical design is a purposeful, reasoning-driven approach to creating drugs. This approach is called rational drug design because decisions about which molecules to make are based on an understanding of how the target's binding site will interact with potential ligands, rather than by trial and error alone. In structure-based drug design, details such as shape, charge, hydrogen-bonding patterns, and hydrophobic regions of the binding pocket inform how a molecule should be arranged to fit snugly and form favorable interactions. This often involves using the target’s crystal structure or other structural data to design ligands that will dock well and selectively inhibit or modulate the target. Non-structure-guided strategies, like empirical drug design, rely more on screening large libraries and observing activity without using detailed structural information; random discovery depends on chance findings; and targeted screening may focus on a subset of compounds but does not inherently imply design based on the target’s geometry. Hence, the most accurate label for structure-based drug design is rational drug design.

Using the target’s 3D structure to guide chemical design is a purposeful, reasoning-driven approach to creating drugs. This approach is called rational drug design because decisions about which molecules to make are based on an understanding of how the target's binding site will interact with potential ligands, rather than by trial and error alone.

In structure-based drug design, details such as shape, charge, hydrogen-bonding patterns, and hydrophobic regions of the binding pocket inform how a molecule should be arranged to fit snugly and form favorable interactions. This often involves using the target’s crystal structure or other structural data to design ligands that will dock well and selectively inhibit or modulate the target.

Non-structure-guided strategies, like empirical drug design, rely more on screening large libraries and observing activity without using detailed structural information; random discovery depends on chance findings; and targeted screening may focus on a subset of compounds but does not inherently imply design based on the target’s geometry. Hence, the most accurate label for structure-based drug design is rational drug design.